Skip to main content

Table 2 Recurrence rate according to the grade of venous invasion

From: Risk stratification for predicting postoperative recurrence/metastasis of colorectal cancer by grade of venous invasion coupled with histological subtype

  Grade of venous invasion Total
  v0 v1 v2 v3
WMDA      
 *Recurrence (%) 8/68 (11.8%) 9/57 (15.8%) 17/23 (73.9%) 3/4 (75.0%) 37/152 (24.3%)
  RR (95% CI) Reference 1.342 (0.565–3.200) 6.283 (3.364–10.834) 6.375 (2.209–9.023)  
  **p value   0.604  < 0.001 0.010  
 Median DTR (range) 438.5 (268–1264) 593 (105–2212) 232 (18–2561) 300 (51–368) 374 (18–2561)
PDA      
 Recurrence (%) 5/18 (27.8%) 17/52 (32.7%) 6/18 (33.3%) 6/10 (60.0%) 34/98 (34.7%)
  RR (95% CI) Reference 1.177 (0.555–2.839) 1.200 (0.455–3.217) 2.160 (0.874–4.695)  
  p value   0.776 1.000 0.125  
 Median DTR (range) 608 (195–3407) 341 (123–1070) 207.5 (139–539) 142.5 (87–297) 244 (87–3407)
MUA      
 Recurrence (%) 5/33 (15.2%) 8/26 (30.8%) 2/5 (40.0%)   15/64 (23.4%)
  RR (95% CI) Reference 2.031 (0.781–5.423) 2.640 (0.645–7.310)   
  p value   0.209 0.223   
 Median DTR (range) 547 (423–1600) 582.5 (22–993) 633.5 (282–985)   572 (22–1600)
SRCC      
 Recurrence (%) 0/1 (0.0%) 2/6 (33.3%) 0/1 (0.0%) 1/1 (100.0%) 3/9 (33.3%)
  RR (95% CI) Reference N.A N.A N.A  
  p value      
 Median DTR (range)   785.5 (436–1135)   2710 (2710–2710) 1135 (436–2710)
  1. WMDA well-to-moderately differentiated adenocarcinoma, PDA poorly differentiated adenocarcinoma, MUA mucinous adenocarcinoma, SRCC signet-ring cell carcinoma, RR relative risk, CI confidence interval, DTR days to recurrence, N.A not applicable, v0 no venous invasion, v1 1–3 invasions/glass slide, v2 4–6 invasions/glass slide, v3 ≥ 7 invasions/glass slide
  2. The filling type of venous invasion in a macroscopically identifiable vein with a minor axis of ≥ 1 mm raised the grade of a v1 or v2 by 1
  3. *In this study cohort, there were no cases of local recurrence throughout the histological subtypes. Therefore, recurrence means distant metastasis due to hematogenous/lymphatic spread or peritoneal dissemination
  4. **Statistical analysis was performed by Fisher's exact test